James E. Galvin

1

Article

0

Comments
Alzheimer’s disease is an incapacitating, progressive brain disorder that affects the lives of more than 6.5 million Americans. PamelaJoeMcFarlane/E+ via Getty Images

What the FDA’s accelerated approval of a new Alzheimer’s drug could mean for those with the disease – 5 questions answered about lecanemab

James E. Galvin, University of Miami

In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.

Contact James for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision